MedinCell S.A.

https://www.medincell.com/

MedinCell S.A. is a French biopharmaceutical company dedicated to enhancing global health through the development of innovative long-acting injectable treatments. Headquartered in Jacou, France, the company's core mission is to improve treatment adherence and accessibility while minimizing the environmental impact of pharmaceuticals. MedinCell focuses on creating therapeutic solutions that address critical medical challenges worldwide.

The company's proprietary BEPO® technology platform is central to its operations, enabling the controlled and prolonged release of active pharmaceutical ingredients for days, weeks, or months from a single subcutaneous injection. This technology underpins a diverse pipeline of product candidates across various therapeutic areas, including psychiatry, pain management, contraception, and infectious disease prevention. Its key commercial product, UZEDY® (risperidone LAI), approved by the FDA in April 2023 and marketed by Teva Pharmaceuticals, is used for the treatment of schizophrenia and bipolar I disorder. The pipeline also includes mdc-TJK (olanzapine LAI) for schizophrenia and mdc-CWM (celecoxib LAI) for post-operative pain, both in Phase 3 clinical trials, as well as preclinical programs like mdc-WWM for contraception and mdc-STM for malaria.

Led by CEO Christophe Douat, MedinCell is actively expanding its market presence and pipeline. Recent notable developments include UZEDY® achieving $63 million in net sales in Q1 2026, a 62% year-on-year increase, and the FDA's acceptance of Teva's New Drug Application for Olanzapine Extended-Release Injectable Suspension in February 2026. The company successfully completed a €48 million private placement in March 2026 to support its growth strategy and has established strategic collaborations with major pharmaceutical companies like Teva Pharmaceuticals and AbbVie, as well as foundations such as the Bill & Melinda Gates Foundation. MedinCell is positioned as an emerging leader in the long-acting injectable therapeutics market, aiming to redefine treatment standards globally.

Latest updates

UZEDY Sales Surge Fuels Medincell Royalty Stream, FDA Decisions Loom

Event summary

  • UZEDY U.S. net sales reached $63 million in Q1 2026, a 62% year-over-year increase from $39 million in Q1 2025.
  • Q4 2025 sales were $55 million, representing a 15% increase from Q1 2026.
  • Medincell receives mid-to-high single-digit royalties on UZEDY sales and is eligible for up to $105 million in milestone payments.
  • The FDA accepted Teva’s NDA for once-monthly olanzapine LAI for schizophrenia in February 2026, with a decision expected in Q4 2026.
  • A Marketing Authorization Application (MAA) for olanzapine LAI is expected to be accepted in Europe in Q2 2026.

The big picture

Medincell's reliance on Teva for UZEDY sales highlights the risks inherent in licensing models within the pharmaceutical industry. The strong Q1 2026 sales demonstrate the potential of long-acting injectable therapies for schizophrenia and bipolar disorder, a market valued at billions annually. The pending FDA decision on olanzapine LAI represents a significant near-term catalyst for Medincell’s valuation, but success is contingent on Teva’s commercial execution and regulatory approvals.

What we're watching

Regulatory Headwinds
The FDA’s decision on the olanzapine LAI NDA in Q4 2026 will be critical, as approval would significantly expand Medincell’s revenue potential through royalties and milestone payments.
Execution Risk
The pace at which Teva can continue to drive UZEDY sales growth will directly impact Medincell’s royalty income and milestone payment eligibility, requiring close monitoring of market penetration and adoption rates.
Financial Capacity
Medincell's ability to manage its financial resources and reinvest in pipeline development will be tested as it relies on UZEDY royalties and milestone payments for funding.

Degroof Petercam Initiates Coverage, Signals Growing Investor Interest in Medincell

Event summary

  • Degroof Petercam, a European investment bank, has initiated coverage of Medincell with a ‘Buy’ recommendation.
  • Medincell is a commercial- and clinical-stage biopharmaceutical company focused on long-acting injectable treatments.
  • The company’s risperidone LAI treatment, marketed as UZEDY® by Teva, received FDA approval in April 2023 and subsequent approval for Bipolar I Disorder in October 2025.
  • Teva submitted an NDA for Olanzapine LAI to the U.S. FDA in December 2025, which was accepted on February 20, 2026.

The big picture

The initiation of coverage by Degroof Petercam suggests growing institutional interest in Medincell, particularly within the European market. This move validates the company’s strategy of expanding its presence in global capital markets and reflects the increasing demand for long-acting injectable therapies to improve patient adherence and treatment outcomes. The acceptance of Teva’s NDA for Olanzapine LAI further reinforces the potential of Medincell’s BEPO® technology and its ability to disrupt the antipsychotic market.

What we're watching

Regulatory Headwinds
The FDA’s review of Teva’s Olanzapine LAI NDA will be a key catalyst for Medincell’s stock performance, and any delays or rejections could negatively impact investor sentiment.
Execution Risk
Medincell’s ability to successfully advance its investigational pipeline and secure further licensing partnerships will be crucial for long-term growth and shareholder value.
Market Dynamics
How effectively Medincell can expand the adoption of its BEPO® technology beyond risperidone and olanzapine will determine its competitive positioning within the long-acting injectable market.

Medincell to Detail Long-Acting Injectable Pipeline at Upcoming R&D Day

Event summary

  • Medincell will host an online R&D Day on May 12, 2026, focusing on its Long-Acting Injectable (LAI) technologies.
  • The event will cover R&D execution, pipeline strategy, partnership models, and intellectual property protection.
  • Risperidone LAI (UZEDY®), utilizing Medincell’s BEPO® technology, is already marketed in the US, Canada, and South Korea.
  • Teva submitted an NDA for Olanzapine LAI to the U.S. FDA in December 2025, which was accepted in February 2026.

The big picture

Medincell operates in a growing market for long-acting injectable therapies, driven by the need to improve patient adherence and reduce healthcare costs. The company’s reliance on partnerships, particularly with Teva, represents both an opportunity for rapid commercialization and a potential source of dependency. The acceptance of the Olanzapine LAI NDA signals continued momentum, but the company's ability to expand its pipeline and protect its intellectual property will be critical for long-term success.

What we're watching

Regulatory Risk
The FDA’s review of Teva’s Olanzapine LAI NDA will be a key indicator of Medincell’s broader regulatory prospects and the viability of its LAI technology for other antipsychotics.
Partnership Dynamics
The success of the Teva partnership, particularly regarding commercialization and royalty structures, will influence Medincell’s approach to future collaborations.
Execution Risk
The R&D Day presentation will reveal the extent to which Medincell can translate its BEPO® technology into a diversified pipeline of LAI treatments beyond risperidone and olanzapine.

Medincell Warrant Settlement Waiver Removes Contingent Liability

Event summary

  • Medincell received a waiver from the European Investment Bank (EIB) regarding put options on approximately 780,000 warrants issued in 2022 as part of a €40 million financing agreement.
  • The waiver eliminates a potential contingent repayment obligation for Medincell, removing a cash settlement requirement at the loan’s maturity.
  • The warrant agreement now allows for earlier exercise and free transferability (subject to shareholder approval expected by September 2026).
  • The amendment has no immediate impact on Medincell’s cash position or operating activities.

The big picture

The EIB’s waiver represents a significant de-risking event for Medincell, providing greater financial flexibility as the company expands its commercial footprint with products like risperidone LAI and progresses its pipeline. This move underscores the increasing scrutiny of contingent liabilities in biopharmaceutical financing and highlights the importance of maintaining strong relationships with key investors. The decision also suggests a shift in the EIB’s investment strategy, potentially favoring more flexible terms for future engagements.

What we're watching

Shareholder Approval
The success of the transferability provision hinges on shareholder approval by September 2026; failure to secure this could reinstate the original warrant terms and associated obligations.
Financial Profile
How the removal of this contingent liability impacts Medincell’s credit rating and future financing options warrants observation, particularly as the company scales its commercial operations.
Partner Dynamics
The EIB’s decision signals continued confidence in Medincell, but the long-term implications of this evolving relationship on future collaborations and financing structures should be monitored.

Medincell Secures €48 Million Private Placement from Specialist Investors

Event summary

  • Medincell successfully raised €48 million through a private placement to international institutional investors.
  • The placement involved the issuance of 2,370,000 new ordinary shares at a price of €20.35 per share, representing a 10% discount.
  • Key investors include Perceptive Advisors, Kurma Growth Opportunities Fund, Affinity Asset Advisors, and Polar Capital, alongside existing shareholders.
  • Proceeds will be used to expand partnering opportunities, optimize future partnerships, and strengthen Medincell’s LAI technology platform.
  • The placement results in a dilution of existing shareholders, with the largest pre-offer shareholders seeing a slight reduction in their ownership percentage.

The big picture

Medincell’s private placement underscores the continued investor appetite for specialized biopharma companies focused on long-acting injectable therapies, a segment gaining traction due to improved patient adherence and reduced healthcare costs. The €48 million injection provides a significant war chest for Medincell to pursue its growth strategy, but the dilution and discounted share price highlight the ongoing scrutiny and risk associated with early-stage biopharmaceutical development and licensing models.

What we're watching

Partnership Dynamics
The stated intent to optimize economics and prioritize royalty participation in future partnerships suggests Medincell may be seeking to shift deal structures, potentially impacting future revenue recognition and partner relationships.
Technology Risk
The commitment to next-generation LAI technologies carries inherent development risk; success is not guaranteed and delays or failures could impact Medincell’s long-term competitive advantage.
Shareholder Sentiment
The discount on the share price and subsequent dilution may weigh on investor sentiment in the near term, requiring Medincell to demonstrate tangible progress against its stated objectives to regain confidence.

Medincell Launches €60M Private Placement to Fuel LAI Platform Expansion

Event summary

  • Medincell is launching a private placement of approximately 6% of its share capital, targeting international institutional investors via an accelerated book-building process.
  • The placement aims to raise roughly €60 million (based on current share price) to support Medincell’s growth strategy.
  • Proceeds will be allocated to expanding partnering opportunities, optimizing partnership economics, and strengthening the proprietary LAI technology platform.
  • The placement is being conducted without pre-emptive rights and is subject to market conditions, with pricing to be determined.
  • The move follows FDA acceptance of Teva’s NDA for Olanzapine LAI, expected for review within approximately eight months.

The big picture

Medincell's shift towards a royalty-driven business model, coupled with this private placement, signals a strategic pivot away from pure technology licensing. The company is attempting to capitalize on the growing long-acting injectable (LAI) market, currently valued at billions, by expanding its platform and securing lucrative partnerships. This capital raise provides a runway to execute this strategy, but hinges on successful regulatory approvals and commercialization of its partnered products.

What we're watching

Partnership Dynamics
The success of Medincell’s growth strategy hinges on its ability to secure and optimize future partnerships, particularly given the allocation of proceeds towards improved economics and royalty participation. The performance of Teva’s UZEDY® sales will be a key indicator of this success.
Regulatory Risk
The FDA review of Olanzapine LAI represents a critical inflection point; a potential delay or rejection could significantly impact Medincell’s revenue projections and investor sentiment.
Technology Adoption
The company's stated focus on next-generation LAI technologies carries execution risk; the pace at which these innovations translate into commercially viable products will determine Medincell’s long-term competitive advantage.

Medincell to Present at Investor Conferences Amidst Olanzapine LAI Review

Event summary

  • Medincell will participate in the Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, from March 8-11, 2026.
  • CEO Christophe Douat and Chief Strategy Officer Grace Kim will be available for investor meetings.
  • Medincell’s risperidone LAI (UZEDY®) received FDA approval for schizophrenia in April 2023 and Bipolar I Disorder in October 2025.
  • A New Drug Application (NDA) for Olanzapine LAI, developed in partnership with Teva, was submitted to the FDA in December 2025 and accepted on February 20, 2026.

The big picture

Medincell's strategy of licensing its BEPO® technology to established pharmaceutical companies like Teva allows it to focus on innovation while leveraging their commercial infrastructure. The upcoming FDA decision on Olanzapine LAI represents a significant milestone, potentially validating the platform and opening doors for further partnerships. The long-acting injectable market is experiencing increased demand as clinicians seek to improve patient adherence and outcomes, creating a favorable environment for Medincell's technology.

What we're watching

Regulatory Risk
The FDA’s review of Teva’s Olanzapine LAI NDA will be a key catalyst for Medincell’s valuation, and any unexpected delays or requests for additional data could negatively impact investor sentiment.
Commercial Execution
How effectively Teva commercializes UZEDY® will directly influence Medincell’s royalty revenue and demonstrate the viability of its BEPO® / BEPO® Star technology platform.
Pipeline Expansion
The pace at which Medincell advances its investigational pipeline beyond risperidone and olanzapine will be crucial for long-term growth and diversification of revenue streams.

Teva's Olanzapine Injectable Secures FDA NDA Acceptance, Bolstering Adherence Strategy

Event summary

  • The FDA has accepted Teva's New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia treatment.
  • TEV-'749 utilizes Medincell’s SteadyTeq™ technology for controlled drug release.
  • Phase 3 SOLARIS trial data demonstrated efficacy and safety consistent with existing olanzapine formulations, without requiring post-injection monitoring.
  • The drug aims to address a critical treatment gap by improving adherence and stability for schizophrenia patients, currently lacking a long-acting olanzapine option without REMS.

The big picture

The acceptance of TEV-'749 represents a significant step in addressing the persistent challenge of treatment adherence in schizophrenia, a market with a substantial unmet need and a global prevalence of approximately 1%. Medincell’s SteadyTeq™ technology, licensed to Teva, is increasingly recognized as a valuable platform for developing improved drug delivery systems across various therapeutic areas. The lack of a long-acting olanzapine formulation without REMS has historically limited treatment options, and TEV-'749 aims to fill this gap, potentially improving patient outcomes and reducing healthcare costs associated with relapses.

What we're watching

Regulatory Review
The FDA review process will be critical; any requests for additional data or concerns raised could significantly impact the approval timeline and potential market access.
Commercialization
Teva's ability to effectively market and distribute TEV-'749, particularly given the need for patient and physician education around a new administration method, will determine its commercial success.
Competitive Landscape
The emergence of alternative long-acting antipsychotics and the potential for biosimilar competition will influence TEV-'749’s long-term market share and pricing power.

Medincell's ESG Rating Boost Signals Growing Investor Scrutiny

Event summary

  • Medincell received an upgraded ESG rating from ISS, moving from C+ to B.
  • The company now ranks within the first decile of the Pharmaceuticals & Biotechnology sector and holds ISS ESG Prime Status.
  • The upgrade reflects Medincell’s performance across social, governance, and environmental criteria, based on publicly available data.
  • The risperidone LAI (UZEDY®) treatment, utilizing Medincell’s BEPO® technology, received FDA approval in April 2023 and subsequent approvals in Canada and South Korea in 2025.

The big picture

The upgrade highlights the growing importance of ESG considerations for biopharmaceutical companies, particularly as institutional investors increasingly incorporate these factors into their investment decisions. Medincell’s ranking within the top decile of its sector demonstrates a commitment to sustainability that could provide a competitive advantage. The focus on long-acting injectable treatments, which inherently reduce environmental impact through less frequent administration, aligns with broader sustainability goals.

What we're watching

Investor Sentiment
The improved ESG rating may attract a broader range of institutional investors, potentially impacting Medincell’s valuation and access to capital, but the market's reaction will depend on broader macroeconomic conditions.
Regulatory Scrutiny
Continued adherence to ISS ESG criteria will be crucial, as regulatory bodies and investors increasingly integrate ESG factors into their assessments, potentially leading to further rating adjustments.
Pipeline Execution
The success of the Olanzapine LAI NDA submission and subsequent commercialization will be a key test of Medincell’s operational capabilities and ability to deliver on its growth strategy, which will be viewed through an ESG lens.

UZEDY Sales Surge Fuels Medincell Royalty Stream, Eyes European Expansion

Event summary

  • UZEDY® net sales reached $191 million in 2025, a 63% increase from $117 million in 2024.
  • Teva projects UZEDY® net sales of $250 - $280 million in 2026.
  • Medincell receives mid-to-high single-digit royalties on UZEDY® sales and is eligible for up to $105 million in milestone payments.
  • Teva plans to submit Olanzapine LAI for EU approval in Q2 2026.
  • Teva submitted an NDA for Olanzapine LAI to the FDA in December 2025.

The big picture

Medincell’s reliance on Teva for UZEDY® sales highlights the inherent risks of a licensing model, but the substantial revenue growth demonstrates the potential of its BEPO® technology. The planned EU expansion for Olanzapine LAI represents a significant opportunity to broaden Medincell’s revenue base, but success hinges on navigating European regulatory hurdles and competitive pressures within the antipsychotic market.

What we're watching

Regulatory Headwinds
The EMA review process, including the CHMP opinion, will be critical; delays could significantly impact Medincell’s milestone payment schedule and overall revenue projections.
Execution Risk
Teva’s ability to achieve its 2026 sales forecast for UZEDY will directly influence Medincell’s royalty income and milestone eligibility, requiring close monitoring of market uptake and competitive dynamics.
Market Dynamics
How the introduction of Olanzapine LAI impacts the broader schizophrenia treatment landscape and potentially cannibalizes existing olanzapine sales will shape Medincell’s long-term revenue streams.
CID: 599